Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

NCT01159600 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1504

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Placebo identical to BI 10773 high dose
DRUG: Placebo identical to BI 10773 low dose
DRUG: BI 10773
DRUG: BI 10773
DRUG: Placebo identical to BI 10773 low dose
DRUG: BI 10773
DRUG: Placebo identical to BI 10773 high dose

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]